Analyzing Kiromic BioPharma (NASDAQ:KRBP) and LogicBio Therapeutics (NASDAQ:LOGC) – Defense World

LogicBio Therapeutics (NASDAQ:LOGC Get Rating) and Kiromic BioPharma (NASDAQ:KRBP Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

This table compares LogicBio Therapeutics and Kiromic BioPharmas net margins, return on equity and return on assets.

This table compares LogicBio Therapeutics and Kiromic BioPharmas top-line revenue, earnings per share (EPS) and valuation.

55.2% of LogicBio Therapeutics shares are owned by institutional investors. Comparatively, 16.0% of Kiromic BioPharma shares are owned by institutional investors. 8.1% of LogicBio Therapeutics shares are owned by insiders. Comparatively, 3.5% of Kiromic BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

LogicBio Therapeutics has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Kiromic BioPharma has a beta of -0.27, indicating that its stock price is 127% less volatile than the S&P 500.

This is a summary of recent ratings and recommmendations for LogicBio Therapeutics and Kiromic BioPharma, as provided by MarketBeat.

LogicBio Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 1,513.16%. Given LogicBio Therapeutics higher probable upside, research analysts clearly believe LogicBio Therapeutics is more favorable than Kiromic BioPharma.

LogicBio Therapeutics beats Kiromic BioPharma on 7 of the 12 factors compared between the two stocks.

(Get Rating)

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

(Get Rating)

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Originally posted here:
Analyzing Kiromic BioPharma (NASDAQ:KRBP) and LogicBio Therapeutics (NASDAQ:LOGC) - Defense World